ImmuPharma says pre-clinical study points to other indications for lead drug

04:02 EDT 14 Jun 2018 | Proactive Investors

Currently being developed to treat lupus, peptide P140 may hold the potential to treat another painful autoimmune disease

More From BioPortfolio on "ImmuPharma says pre-clinical study points to other indications for lead drug"